News | September 08, 2008

First Cases Completed in Australia, New Zealand Using ReValving System for Percutaneous Aortic Valve Replacement

September 9, 2008 - CoreValve said today five clinical evaluation sites (two in New Zealand and three in Australia) have now completed their first series of proctored cases using the company’s proprietary ReValving System for percutaneous aortic valve replacement (PAVR), which features a porcine pericardium valve mounted in a self-expanding frame.

During a 12-day period, 24 patients at hospitals in Auckland, Brisbane, Melbourne, Sydney and Hamilton underwent successful percutaneous aortic valve replacement with CoreValve’s ReValving System. These hospitals are participating in a clinical evaluation registry as required for market clearance in Australia and New Zealand. To date, more than 1,500 patients at 75 sites worldwide have now received a ReValving bioprosthesis since the CE mark was issued.

Physicians will be presenting CoreValve clinical data at the 22nd EACTS (European Association for Cardio-Thoracic Surgery) Annual Meeting in Lisbon, Portugal, which begins Sept. 13.

For more information

Related Content

First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
Overlay Init